Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Spinal cord injuries are the injuries caused to the thirty one pairs of spinal nerves, which carry nerve signals from brain to various parts of the body and also controls the arm and leg movements. The main cause of spinal cord injuries include trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections. Spinal cord injuries can be diagnosed with the help of various techniques such as X-ray, magnetic resonance index (MRI), and computed tomography (CT).

The increasing prevalence of traumatic spinal cord injuries is expected to drive the market growth over the forecast period. For instance, according to the U.S. National Library of Medicine report published in 2018, the prevalence of traumatic spinal cord injuries in low and middle economic economies such as Algeria, Bangladesh, and others was 8.72% per 100,000 individuals and prevalence of traumatic spinal cord injuries in high income countries such as Bermuda (U.K.), Switzerland, and others was 13.69% per 100,000 individuals, globally in the year 2018.

The global spinal cord injury therapeutics market is estimated to be valued at US$ 6,784.2 million in 2021 and is expected to exhibit a CAGR of 5.1% over the forecast period (2021-2028).

Figure 1. Global Spinal Cord Injury Therapeutics Market Share (%) in Terms of Value, By Region, 2021

Spinal Cord Injury Therapeutics  | Coherent Market Insights

The robust product pipeline for the treatment of spinal cord injury, which are estimated to launch over the forecast period is expected to drive the growth of the global spinal cord injury therapeutics market.

For instance, in July 2020, Kringle Pharma Inc., a late clinical-stage biopharmaceutical company, initiated a phase III clinical trial study of KP-100IT HGF protein for the treatment of patients suffering from acute spinal cord injury. The study is estimated to complete by September 30, 2022.

Furthermore, on March 7, 2018, Eusol Biotech Co., Ltd., a biopharmaceutical company, initiated a phase III clinical trial study to evaluate the safety and efficacy of ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) in patients with spinal cord injury. The study is estimated to complete by December 31, 2024.

request-sample

Spinal Cord Injury Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 6,784.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 5.1% 2028 Value Projection: US$  9,611.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Injury Type: Complete Spinal Cord Injury, Incomplete Spinal Cord Injury
  • By Drug Type: Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs (NSAIDs), Anti-depressants, Anticonvulsants, Others
  • By Application: Autonomic Dysreflexia (AD), Spasticity & Inflammation, Pain Management, Depression
  • By Route of Administration: Oral, Intravenous
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.

Growth Drivers:
  • Increasing prevalence of traumatic spinal cord injuries
  • Robust product pipeline
Restraints & Challenges:
  • Potential side effects of drugs used in the treatment of spinal cord injury 

Figure 2. Global Spinal Cord Injury Therapeutics Market Share (%), by Injury Type, 2021

Spinal Cord Injury Therapeutics  | Coherent Market Insights

The rising government investments in key companies to promote research and development for treatment of spinal cord injuries is expected to offer a lucrative opportunity for the market players to develop novel therapeutics for the treatment of spinal cord injury. 

For instance, in 2018, BioAxone BioSciences, Inc. announced that they had received two-year grant of US$ 1.1 Million, which provides funding for further development of BioAxone's preclinical candidate BA-434, a novel sd-rxRNA compound that targets phosphatase and tensin homolog (PTEN) for the treatment of spinal cord injury (SCI). The funding was granted from the National Institute of Neurological Disorders and Stroke (NINDS), a part of the U.S. National Institutes of Health.

Global Spinal Cord Injury Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic- Government Measures to Combat COVID-19

Governments are taking various initiatives to combat COVID-19. For instance, in May 2020, the Centers for Disease Control and Prevention started working with the All-of-Government and All-of-America Approach to increase testing capacity, improve case detection, and contact tracing across all states in the U.S. and to re-open the country.

Moreover, in April 2020, United Spinal received a generous grant from the Craig H. Neilsen Foundation to provide relief to people living with spinal cord injuries and disorders (SCI/D) who have experienced hardships due to the COVID-19 pandemic.

Global Spinal Cord Injury Therapeutics Market Restraint

Drugs such as corticosteroids, non-steroidal anti-inflammatory drugs, anti-depressants, and anticonvulsants are used in the treatment of spinal cord injury. These drugs have a wide range of curable and permanent side effects on the body of the patient, who is continuously taking more than the prescribed dose of these drugs for a longer period of time. This is expected to restrain the market growth during the forecast period.

Epidural steroids injections (by which corticosteroids are administered) are mostly used in the treatment of spinal cord injury. Potential complications and adverse events associated with epidural steroids injections include bleeding, dural puncture nerve damage, cardiovascular system (heart) complications, risk associated with local anesthetics, and risk associated with steroids. Risks and complications are typically higher in epidural steroid injections administered above the L3 level.

Key Players

Major players operating in the global spinal cord injury therapeutics market include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.

The global spinal cord injury therapeutics market comprises therapeutics used for the treatment of spinal cord injury such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAID’S), muscle relaxants, and anti-depressants. There are two types of spinal cord injuries including complete spinal cord injury and incomplete spinal cord injury and various causes of spinal cord injuries include brain injury, trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global spinal cord injury therapeutics market. For instance, in September 2020, AbbVie Inc., received an orphan drug and fast track designation from the U.S. Food and Drug Administration for Elezanumab, an investigational monoclonal antibody RGMa inhibitor for the treatment of spinal cord injury.

Key features of the study:

  • This report provides in-depth analysis of the global spinal cord injury therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global spinal cord injury therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global spinal cord injury therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal cord injury therapeutics market

Detailed Segmentation:

  • Global Spinal Cord Injury Therapeutics Market, By Injury Type:
    • Complete Spinal Cord Injury
    • Incomplete Spinal Cord Injury
  • Global Spinal Cord Injury Therapeutics Market, By Drug Type:
    • Corticosteroids
    • Muscle Relaxants and Anti-spastic drugs
    • Non-steroidal Anti-inflammatory drugs (NSAIDs)
    • Anti-depressants
    • Anticonvulsants
    • Others
  • Global Spinal Cord Injury Therapeutics Market, By Application:
    • Autonomic Dysreflexia (AD)
    • Spasticity & Inflammation
    • Pain Management
    • Depression
  • Global Spinal Cord Injury Therapeutics Market, By Route of Administration:
    • Oral
    • Intravenous
  • Global Spinal Cord Injury Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Spinal Cord Injury Therapeutics Market, By Region:
    • North America
      • By Injury Type
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs (NSAIDs)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration
        • Oral
        • Intravenous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Injury Type
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs (NSAIDs)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration
        • Oral
        • Intravenous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Injury Type
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs (NSAIDs)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration
        • Oral
        • Intravenous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Injury Type
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs (NSAIDs)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration
        • Oral
        • Intravenous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Injury Type
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs (NSAIDs)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration
        • Oral
        • Intravenous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Injury Type
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs (NSAIDs)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration
        • Oral
        • Intravenous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • AbbVie Inc.
    • Pfizer Inc.
    • Reddy's Laboratories Ltd.
    • Zydus Cadila
    • ReNetX Bio, Inc.
    • InVivo Therapeutics Holdings
    • Lineage Cell Therapeutics, Inc.
    • Kringle Pharma, Inc.
    • Acorda Therapeutics, Inc.
    • Bioaxone Biosciences, Inc.
    • RespireRx Pharmaceuticals Inc.
    • NervGen
    • Rising Pharmaceuticals, Inc.
    • ScieGen Pharmaceuticals, Inc.
    • MSN Laboratories Private Limited
    • Lannett Co Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Injury Type
      • Market Snippet, By Drug Type
      • Market Snippet, By Application
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Epidemiology
    • Product Launch/Approvals
    • Key Developments
    • Reimbursement Scenario
  4. Global Spinal Cord Injury Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Impact on Overall Healthcare Market
    • COVID-19 Impact on Spinal Cord Market
    • Government Initiative To Combat Covid-19
  5. Global Spinal Cord Injury Therapeutics Market, By Injury Type, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Complete Spinal Cord Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Incomplete Spinal Cord Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  6. Global Spinal Cord Injury Therapeutics Market, By Drug Type, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Muscle Relaxants and Anti-spastic drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Non-steroidal Anti-inflammatory drugs (NSAID’S)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Anti-depressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Anticonvulsants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  7. Global Spinal Cord Injury Therapeutics Market, By Application, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Autonomic Dysreflexia (AD)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Spasticity & Inflammation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Pain Management
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Depression
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  8. Global Spinal Cord Injury Therapeutics Market, By Route of Administration, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  9. Global Spinal Cord Injury Therapeutics Market, By Distribution Channel, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  10. Global Spinal Cord Injury Therapeutics Market, By Region, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
    • North America
      • Market Size and Forecast, By Injury Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Injury Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Injury Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Injury Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Injury Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Injury Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Application, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2021 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  11. Competitive Landscape
    • Competitive Snapshot
      • Teva Pharmaceutical Industries Ltd.*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reddy's Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Zydus Cadila
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ReNetX Bio, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • InVivo Therapeutics Holdings
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lineage Cell Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kringle Pharma, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Acorda Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bioaxone Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RespireRx Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NervGen
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Rising Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ScieGen Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MSN Laboratories Private Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lannett Co Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  12. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 53 market data tables and 43 figures on "Spinal Cord Injury Therapeutics Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global spinal cord injury therapeutics market size is estimated to be valued at US$ 6,784.2 million in 2021 and is expected to exhibit a CAGR of 5.1% between 2021 and 2028.
Increasing prevalence of traumatic spinal cord injuries and robust product pipeline are expected to drive the market growth over the forecast period.
Complete spinal cord injury segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the market include potential side effects of drugs used in the treatment of spinal cord injury.
Major players operating in the market include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.